Bisdemethoxycurcumin Compositions for Managing Chronic Obstructive Pulmonary Disease (EP4090340A1)

The EPO published patent application EP4090340A1, granting Sami-Sabinsa Group Limited exclusive intellectual property rights to bisdemethoxycurcumin compositions for COPD treatment. The patent is classified under IPC category A61K 31/12 and designates 37 European contracting states including all EU member states, Switzerland, Norway, Turkey, and others.\n\nAffected parties—including pharmaceutical companies, contract manufacturers, and researchers in the COPD therapeutic space—should be aware that commercial use of bisdemethoxycurcumin compositions for COPD management may now be restricted by valid IP rights in designated EPO member states. Freedom-to-operate analyses should be updated to account for this granted patent when developing or commercialising related therapeutic products.